Out of these 77 were diagnosed as deep venous thrombosis
and 19 as pulmonary embolism.
The etiology of acute mesenteric ischemia can be divided into four categories: arterial embolization, arterial thrombosis, mesenteric venous thrombosis
, and non-occlusive, low-flow state.
Point of Care Ultrasound (POCUS) for the diagnosis of suspected lower extremity deep venous thrombosis
(DVT) is a well-established practice in the medical literature.
Venous thromboembolism (VTE), including deep venous thrombosis
(DVT) and pulmonary embolism (PE), is a frequent and important health problem in the world, as well as in Croatia, with estimated incidence between 1 and 2 per 1000 individuals per year (1-8).
For example, heterozygous carriers of the F2G20210A mutation have 30% higher plasma prothrombin levels than normal and an increased risk of venous thrombosis
A study from India put the incidence of venous thrombosis
18,20) MR venography can demonstrate absence of flow in occluded sinus and vessels, and contrast-enhanced MR venography can further differentiate venous thrombosis
from normal anatomic variants such as a hypoplastic sinus.
This is important in protecting against arterial thrombosis, but far less so for venous thrombosis
KEY WORDS: Risk factors, Protective factors, Deep venous thrombosis
Batool et al found deep venous thrombosis
(DVT) as the cause of painful swollen leg in 46% of the patients5.
Deep venous thrombosis
(DVT), characterized by a blood clot which forms in deep veins (leg or pelvis) in the body, is a major medical problem worldwide.
Hughes-Stovin syndrome (HSS) is an extremely rare condition, characterized by multiple pulmonary artery aneurysms and peripheral venous thrombosis
, which was first described in 1959 by John Patterson Hughes and Peter George Ingle Stovin.
Deep venous thrombosis
annually affects 1 of 1000 individuals (1), causing severe morbidity and potentially lethal pulmonary embolism (1).
Objective: To enlist the dominant risk factors predisposing patients to deep venous thrombosis
has announced that the FDA has approved Pradaxa (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis
(DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days and to reduce the risk of recurrent DVT and PE in patients who have been previously treated.